These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Sintilimab-related diabetes mellitus and psoriasis: A case report and literature review. Huang W, Liu Y, Li M, Xue Y, Bao W, Guo Y. Medicine (Baltimore); 2023 Nov 10; 102(45):e35946. PubMed ID: 37960733 [Abstract] [Full Text] [Related]
25. Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis. Zhang Y, Fang Y, Wu J, Huang G, Bin J, Liao Y, Shi M, Liao W, Huang N. Front Pharmacol; 2022 Nov 10; 13():817662. PubMed ID: 35431928 [Abstract] [Full Text] [Related]
28. The Simultaneous Onset of Pancreatitis and Colitis as Immune-related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma. Yazaki T, Moriyama I, Tobita H, Sonoyama H, Okimoto E, Oka A, Mishima Y, Oshima N, Shibagaki K, Kawashima K, Ishimura N, Nagami T, Maruyama R, Shiina H, Ishihara S. Intern Med; 2022 May 15; 61(10):1485-1490. PubMed ID: 34744104 [Abstract] [Full Text] [Related]
29. Immune Checkpoint Inhibitor-Induced Diabetes Mellitus: Potential Role of T Cells in the Underlying Mechanism. Mourad D, Azar NS, Eid AA, Azar ST. Int J Mol Sci; 2021 Feb 20; 22(4):. PubMed ID: 33672515 [Abstract] [Full Text] [Related]
30. [Two Case Reports of Type 2 Diabetes Induced by Immune Checkpoint Inhibitors Combined with Chemotherapy]. Xiao P, Zhang L, Wang Y, Meng F, Wang X, Zhong D. Zhongguo Fei Ai Za Zhi; 2022 Apr 20; 25(4):287-290. PubMed ID: 35477193 [Abstract] [Full Text] [Related]
31. [Endocrinopathies Associated with Immune Checkpoint Inhibitors]. Santos MJ. Acta Med Port; 2022 Mar 02; 35(3):209-215. PubMed ID: 35077347 [Abstract] [Full Text] [Related]
35. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities. Cooksley T, Girotra M, Ginex P, Gordon RA, Anderson R, Blidner A, Choi J, Dougan M, Glezerman I, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Rapoport BL. Support Care Cancer; 2020 Dec 02; 28(12):6175-6181. PubMed ID: 32856213 [Abstract] [Full Text] [Related]
37. Immune Checkpoint Inhibitors in Cancer Treatment and Incidence of Pancreatitis. Nwankwo OC, Lara-Salazar FM, Lara-Salazar S, Abdulrahim AO, Chijioke I, Singh J, Koradia I, Gomez NM, Prakash R, Gopagoni R, Joshi M, Rai M. Cureus; 2024 Aug 02; 16(8):e68043. PubMed ID: 39347217 [Abstract] [Full Text] [Related]